{"transactions":[{"id":2419533,"issuer":{"id":7801,"kind":"organization","name":"SYNLOGIC, INC."},"owners":[{"id":130953,"kind":"person","name":"BELOFF GREGG","position":1,"cik":"0001171002","reported_name":"BELOFF GREGG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2022-02-01T16:05:31.000Z","date":"2021-12-06","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were issued to the Reporting Person pursuant to the Issuer's 2015 Equity Incentive Award Plan. Such options vest in 12 equal monthly installments starting November 1, 2021, provided the Reporting Person continues to provide services to the Issuer. An aggregate of 50% of the options shall vest immediately if the Issuer terminates the Reporting Person's services before May 1, 2022."}],"balance_after":50000,"derivative":{"exercise_price":2.34,"expiration_date":"2031-12-06","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-22-003838","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1171002/000089924322003838/doc4.xml","form_type":"4"}},{"id":2764715,"issuer":{"id":11788,"kind":"organization","name":"Pandion Therapeutics, Inc.","symbol":"PAND"},"owners":[{"id":130953,"kind":"person","name":"BELOFF GREGG","position":1,"cik":"0001171002","reported_name":"BELOFF GREGG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-04-01T19:53:42.000Z","date":"2021-04-01","kind":"other","acquired":false,"shares":13196,"price":60,"value":791760.0,"ownership":{"direct":false,"nature":"By Danforth Advisors, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated February 24, 2021, among Pandion Therapeutics, Inc. (the \"Company\"), Merck Sharp & Dohme Corp. (\"Merck\") and Panama Merger Sub, Inc. (\"Merger Sub\"), Merger Sub commenced a tender offer (the \"Offer\") to purchase all outstanding Company common stock for the price of $60.00 per share in cash (the \"Offer Price\"). On April 1, 2021, the Offer consummated, after which Merger Sub merged with and into the Company (the \"Merger\") and the Company became a wholly owned subsidiary of Merck. At the consummation of the Offer and the Merger, respectively, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to the Offer Price and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the \"Effective Time\"), were cancelled and converted automatically into the right to receive the Offer Price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-21-014456","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1171002/000089924321014456/doc4.xml","form_type":"4"}},{"id":3388757,"issuer":{"id":7801,"kind":"organization","name":"SYNLOGIC, INC."},"owners":[{"id":130953,"kind":"person","name":"BELOFF GREGG","position":1,"cik":"0001171002","reported_name":"BELOFF GREGG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2019-10-24T19:12:49.000Z","date":"2019-10-23","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vest with respect to 25% of the shares on a date that is 6 months from the date of grant, with the remaining shares to vest in equal monthly installments over the following 18 months, subject to the Reporting Person continuing to provide services to the Issuer as Interim Chief Financial Officer through each such vesting date."}],"balance_after":50000,"derivative":{"exercise_price":2.3,"expiration_date":"2029-10-23","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-19-025927","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1171002/000089924319025927/doc4.xml","form_type":"4"}},{"id":4495250,"issuer":{"id":7799,"kind":"organization","name":"Dare Bioscience, Inc."},"owners":[{"id":130953,"kind":"person","name":"BELOFF GREGG","position":1,"cik":"0001171002","reported_name":"BELOFF GREGG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Stock Option (right to buy)","published_at":"2017-01-09T17:08:43.000Z","date":"2017-01-05","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on January 5, 2017. The option is scheduled to vest as to 25% of the shares on the six-month anniversary of January 1, 2017 and as to an additional 25% of the original number of shares at the end of each six-month period of continuous service thereafter until January 1, 2019."}],"balance_after":50000,"derivative":{"exercise_price":0.82,"expiration_date":"2027-01-04","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-17-002970","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1171002/000120919117002970/doc4.xml","form_type":"4"}}]}